Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone

被引:7
作者
Akahane, Tsutomu [1 ]
Shimizu, Tominaga [1 ]
Isobe, Ken'ichi [1 ]
Yoshimura, Yasuo [1 ]
Kato, Hiroyuki [1 ]
机构
[1] Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano 3908621, Japan
关键词
NON-HODGKINS-LYMPHOMA; RECEPTOR;
D O I
10.1007/s00776-009-1335-x
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
The reliability of selected serum markers and radiological features for distinguishing malignant lymphoma of the bone from other osteolytic bone lesions was examined in an effort to improve the differential diagnosis. A total of 23 patients with histologically verified malignant lymphoma of the bone, 57 patients with other osteolytic malignancies (35 males, 22 females; mean age 62.8 years, range 13-89 years), and 13 patients with benign bone lesions that resemble malignant tumor radiographically (6 men, 7 women; mean age 48.1 years, range 20-73 years) were retrospectively reviewed. We evaluated the serum levels of soluble interleukin-2 receptor (sIL-2R), lactate dehydrogenase, and C-reactive protein in addition to radiographic examination and gallium-67 scanning. Although every clinical feature examined was found to show significant differences between lymphoma and the other two groups, the feature most highly suggestive of malignant lymphoma is a high serum sIL-2R level (sensitivity 0.95, specificity 0.70, accuracy 0.81). The serum sIL-2R level can be a valuable marker for diagnosing malignant lymphoma of the bone.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 12 条
[1]   Case report: Lymphoma masquerading as infection [J].
Blum, YC ;
Esterhai, JL ;
Esmail, AN ;
Lackman, RD ;
Donthineni-Rao, R .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2005, (432) :267-271
[2]   Malignant lymphoma of bone [J].
Dürr, HR ;
Müller, PE ;
Hiller, E ;
Maier, M ;
Baur, A ;
Jansson, V ;
Refior, HJ .
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2002, 122 (01) :10-16
[3]   Primary non-Hodgkin's lymphoma of bone in children [J].
Glotzbecker, MR ;
Kersun, LS ;
Choi, JK ;
Wilis, BP ;
Schaffer, AA ;
Dormans, JP .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2006, 88A (03) :583-594
[4]  
HARRINGTON DS, 1988, ARCH PATHOL LAB MED, V112, P597
[5]   Prognostic significance of serum soluble interleukin-2 receptor level in Non-Hodgkin's lymphoma: A single center study in Japan [J].
Kono, N ;
Kanda, Y ;
Yamamoto, R ;
Chizuka, A ;
Suguro, M ;
Hamaki, T ;
Arai, C ;
Matsuyama, T ;
Takezako, N ;
Miwa, A ;
Togawa, A .
LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) :151-156
[6]   Trends in mortality from non-Hodgkin's lymphomas [J].
Levi, F ;
Lucchini, F ;
Negri, E ;
La Vecchia, C .
LEUKEMIA RESEARCH, 2002, 26 (10) :903-908
[7]  
LEWIS SJ, 1994, CAN J SURG, V37, P43
[8]  
Mirra J., 1989, BONE TUMORS CLIN RAD, P1119
[9]   CLINICAL-SIGNIFICANCE OF SERIAL MEASUREMENT OF THE SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR AND SOLUBLE CD8 IN MALIGNANT-LYMPHOMA [J].
MOTOKURA, T ;
KOBAYASHI, Y ;
FUJITA, A ;
NAKAMURA, Y ;
TANIGUCHI, T ;
UCHIMARU, K ;
ASANO, S .
LEUKEMIA & LYMPHOMA, 1995, 16 (3-4) :355-362
[10]  
PUI CH, 1987, BLOOD, V70, P624